Abstract
The outbreak of COVID-19 has brought various influences to the Biological Medicine industries. any biomedical companies have been fighting on the front lines from beginning to end. This essay uses Mingde Biotechnology Company as the classical case to analyze and compare the Biological Medicine industry’s corporate finance and state of operation before and after COVID-19. Through research, Mingde Biotechnology Company experienced a dramatic profit. Therefore, the conclusion is that COVID-19 gives additional benefits to Biological Medicine industries due to the increasing demand for Nucleic acid tests and some other medical supplies. Nevertheless, because of the wane of the pandemic, the demand for the Nucleic acid test which is also the main business of the Biological Medicine industry, so the meaning of the research is to give more ways for this enterprise to continue to gain profits in the post-pandemic era. Companies benefiting from the epidemic should take advantage of this opportunity to develop more cutting-edge medical products, realize domestic substitution, and better serve the people.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
